Immunisation of renal transplant patients against streptococcus pneumoniae by conjugated or non conjugated pneumococcal vaccination
Conditions
Interventions
Trade Name: Pneumo 23
Pharmaceutical Form: Solution for injection
Trade Name: Prevenar
Pharmaceutical Form: Solution for injection
Sponsors
Medical University of Vienna
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Adult patients will be recruited at the transplant center of the Medical University of Vienna. Patients will be eligable if between 6 months and 3 years had passed since their kidney transplant and if they have stable allograft function, as evidenced by creatinine level =65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: splenectomy, pneumococcal vaccination within preceeding 5 years, any acute febrile illness in the 2 weeks prior to or at time of enrollment, use of intravenous immunoglobulis within precceding 6 months, history of severe allergic reaction or anaphylaxis, hemoglobin value < 10 g/dl at the time of inclusion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To find an optimal vaccination schedule for tranplant patients;Secondary Objective: ;Primary end point(s): The aim of the study is to compare the quantitative antibody response of PPV23 with those of a sequential schedule of PCV7 followed by PPv23 12 months later in adult renal transplant recipients by measuring the concentrations of serotype-specific IgI in sera using ELISA recommended by the WHO. | — |
Countries
Austria
Outcome results
None listed